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Metastasis is a multistep process characterized by the ability of tumor cells to “communicate” and to 
interact with their microenvironment to establish tumors in distant organs. A significant proportion 
of the metastatic microenvironment consists of leukocytes, mostly of the innate immune system, 
contributing to tumor invasion and outgrowth. Chemokines are instrumental for recruiting immune 
cells thereby enabling efficient metastasis [1]. Still, the exact mechanisms of chemokine action in the 
metastatic process have remained elusive. In the context of cancer, chemokines were shown to 
affect leukocyte recruitment, tumor cell proliferation, invasion, angiogenesis and cancer progression 
[2]. In addition, tissue-specific metastasis of certain cancers was shown to depend on specific 
chemokine-chemokine receptor interactions. For instance, the expression of the chemokine receptor 
CXCR4 on breast cancer cells supports metastasis to secondary sites expressing CXCL12 [3]. 
Chemokine-driven leukocyte recruitment in tumors is linked to the major attractors of monocytic 
cells, namely CCL2 and CCL5 [4, 5]. Elevated levels of CCL2 correlated with poor prognosis due to 
metastasis in a variety of cancer patients e.g. suffering from breast and prostate cancer. In a recent 
study we detected elevated levels of CCL2 in biopsies from metastatic colon cancer patients (UICC 
stage IV) [6].  
Still, the different roles of CCL2 and CCL5 during metastasis are just at the beginning to be defined. In 
the tumor microenvironment, stromal cells, infiltrating leukocytes and tumor cells themselves were 
identified as sources of chemokines. During the initial phase of metastasis, local activation of 
endothelia by tumor cells induced endothelial CCL5 expression, resulting in monocyte recruitment 
and promotion of metastasis [7]. Recently, CCL2-mediated recruitment of monocytes has been 
identified as the major factor facilitating breast cancer metastasis to the lung [8], while the exact role 
of monocytes in this process remained unanswered. We showed that monocytes enable tumor cell 
transmigration through the endothelium [6]. Using mouse models we demonstrated that expression 
of CCL2 by colon cancer cells not only attracts pro-inflammatory monocytes but also directly signals 
towards CCR2+ endothelial cells to enable tumor cell extravasation. Importantly, tumor cells were 
unable to efficiently transmigrate through CCR2-deficient endothelial cells, indicating the presence of 
CCR2 on the endothelium is a crucial factor for CCL2-mediated metastasis. Activation of CCR2 on 
endothelial cells through the JAK2-Stat5 and p38MAPK pathway caused increased vascular 
permeability and enhanced tumor cell transmigration in vivo and in vitro. Moreover, blocking of 
signaling pathways downstream of CCR2 significantly reduced metastasis, supporting the notion that 
endothelial CCR2 “licenses” colon cancer extravasation. Consequently, our findings define an 
additional role for chemokines in enabling metastasis that goes beyond the attraction of 
inflammatory leukocytes.  
We confirmed that metastasis of another tumor cell line, Lewis lung carcinoma (3LL), is also 
dependent on CCL2 expression. In contrast, the melanoma cell line B16-BL6 could extravasate and 
metastasize independently of endothelial CCR2 expression. Interestingly, this cell line expresses only 
little CCL2. Our findings raise several questions:  
(1) Do other cancer cells also use chemokine-chemokine receptor interactions to accomplish tumor 
cell extravasation?  
(2) Can we use chemokine expression analysis in primary tumors of patients to predict increase risk 
for metastasis?  
(3) What other chemokine-chemokine receptor pairs exist, having the same or other biological 
function as CCL2-CCR2?  
(4) What do we know about the cellular and spatiotemporal denominators of CCL2-induced tumor 
cell extravasation?  
Consequently, further experiments will show how general our recently reported findings are and 
whether other chemokine receptors on endothelial cells exert similar functions. We hypothesize that 
other functions of tumor cell-derived chemokines will be identified in the future, surpassing their 
known role as immune cell attractors, as the currently identified contribution to induced vascular 
permeability. 
 
References  
 
1. Zlotnik A, Burkhardt AM, Homey B. Nat Rev Immunol. 2011; 11:597-606. 
2. Allavena P, Germano G, Marchesi F, Mantovani A. Exp Cell Res. 2011; 317:664-673. 
3. Muller A, Homey B, Soto H et al. Nature. 2001; 410:50-56. 
4. Soria G, Ben-Baruch A. Cancer Lett. 2008; 267:271-285. 
5. Balkwill F. Nat Rev Cancer. 2004; 4:540-550. 
6. Wolf MJ, Hoos A, Bauer J et al. Cancer Cell. 2012; 22:91-105. 
7. Läubli H, Spanaus KS, Borsig L. Blood. 2009; 114:4583-4591. 
8. Qian BZ, Li J, Zhang H et al. Nature. 2011; 475:222-225. 
 
 
